Clearbridge Investments LLC continued to hold its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,240 shares of the medical equipment provider’s stock at the end of the first quarter. Clearbridge Investments LLC’s holdings in Zimmer Biomet Holdings were worth $151,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock worth $2,044,168,000 after buying an additional 16,336,262 shares during the period. Nordea Investment Management AB raised its stake in shares of Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock worth $602,159,000 after buying an additional 987,398 shares during the period. Glenview Capital Management LLC bought a new stake in shares of Zimmer Biomet Holdings during the first quarter worth about $94,197,000. Point72 Asset Management L.P. raised its stake in shares of Zimmer Biomet Holdings by 230.3% in the first quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock worth $128,643,000 after buying an additional 734,500 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Zimmer Biomet Holdings by 3.7% in the first quarter. Vanguard Group Inc. now owns 13,041,411 shares of the medical equipment provider’s stock worth $1,592,488,000 after buying an additional 464,916 shares during the period. 84.19% of the stock is owned by institutional investors and hedge funds.

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 131.18 on Wednesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.49. The company has a market capitalization of $26.45 billion, a P/E ratio of 53.70 and a beta of 1.21. The stock’s 50 day moving average price is $126.64 and its 200 day moving average price is $120.19.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. The firm had revenue of $1.98 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same quarter in the prior year, the company earned $2.00 EPS. Zimmer Biomet Holdings’s revenue was up 3.8% on a year-over-year basis. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.51 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 23rd will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.73%. The ex-dividend date is Wednesday, June 21st. Zimmer Biomet Holdings’s payout ratio is 39.67%.

TRADEMARK VIOLATION WARNING: “Clearbridge Investments LLC Continues to Hold Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/clearbridge-investments-llc-continues-to-hold-stake-in-zimmer-biomet-holdings-inc-nysezbh/1451784.html.

ZBH has been the subject of a number of research analyst reports. Needham & Company LLC increased their price objective on shares of Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price objective on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday, April 28th. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, April 4th. Goldman Sachs Group, Inc. (The) began coverage on Zimmer Biomet Holdings in a research report on Tuesday, May 16th. They set a “sell” rating and a $92.00 target price for the company. Finally, Wells Fargo & Company downgraded Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research report on Friday, April 28th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $137.77.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David C. Dvorak sold 87,331 shares of the company’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $116.47, for a total value of $10,171,441.57. Following the sale, the insider now owns 381,886 shares in the company, valued at approximately $44,478,262.42. The disclosure for this sale can be found here. In the last three months, insiders have sold 111,262 shares of company stock worth $13,103,927. 1.07% of the stock is owned by corporate insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.